---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-001109"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2026-06-30T12:03:55+00:00"
generated_at: "2026-06-30T12:05:15.769916+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical receives HREC approval to initiate Phase 1 trial of NPM-139 semaglutide implant for obesity

## Summary
- Received approval from Bellberry HREC in Australia to start SLIM-1 Phase 1 trial of NPM-139 semaglutide implant.
- SLIM-1 trial initiation expected mid-2026; builds on prior Phase 1 success with NPM-119 exenatide implant in 2025.
- Company plans SLIM-2 dose-ranging efficacy trial pending SLIM-1 results to accelerate NPM-139 development.
- CEO cites strong market demand for miniature, reversible GLP-1 implant technology.

## SEC filing metadata
- accession: 0001753926-26-001109
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2026-06-30T12:03:55+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001109/0001753926-26-001109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001109/vani-20260624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-001109
- JSON: https://secwatch.observer/filing/0001753926-26-001109.json
- Plain text: https://secwatch.observer/filing/0001753926-26-001109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.